Perkinelmer
PerkinElmer, Inc., a leading global company in the life sciences and diagnostics sectors, is headquartered in the United States. Founded in 1937, PerkinElmer has established itself as a pioneer in providing innovative solutions across various industries, including healthcare, environmental testing, and food safety. With a strong presence in North America, Europe, and Asia, the company offers a diverse range of core products and services, such as analytical instruments, reagents, and software solutions. PerkinElmer's commitment to advancing human and environmental health is reflected in its cutting-edge technologies and comprehensive support services. Recognised for its significant contributions to the field, PerkinElmer has achieved notable milestones, including advancements in genetic testing and diagnostics. This positions the company as a trusted partner in the scientific community, dedicated to improving lives through innovation.
DitchCarbon Score
How does Perkinelmer's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Perkinelmer's score of 36 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Perkinelmer's reported carbon emissions
In 2021, PerkinElmer U.S. LLC reported total greenhouse gas emissions of approximately 29,928,000 kg CO2e, comprising 7,579,000 kg CO2e from Scope 1 and 22,349,000 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming for a 50.4% reduction in Scope 1 and 2 emissions by 2032, with a baseline year of 2020. This target aligns with the latest guidance from the Science Based Targets Initiative (SBTi), which has also set near-term targets for PerkinElmer to reduce absolute Scope 1 emissions by 58.8% and Scope 3 emissions by 63.8% per USD value added by 2034, both from a 2023 base year. Additionally, PerkinElmer is committed to achieving net carbon neutrality by 2040 and plans to increase its sourcing of renewable electricity from 0% in 2023 to 100% by 2030. These initiatives reflect the company's dedication to addressing climate change and reducing its carbon footprint in the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | |
|---|---|---|
| Scope 1 | - | 0,000,000 |
| Scope 2 | - | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Perkinelmer is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
